MedTrace Logo

Danish Hypertension Prevention Project - DHYPP

NCT00150631 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2014-11-26

No results posted yet for this study

Summary

The present study examine healthy, normotensive subjects 18 to 36 years of age whose both parents have essential hypertension. The subjects receive treatment with either the AT1-antagonist candesartan cilexetil, 16 mg daily or placebo for one year. Then, treatment is withdrawn and the subjects is followed for 10 years to determine if the treatment has been able to either prevent or delay the development of hypertension. The primary objective is to determine whether pharmacological treatment with an angiotensin receptor blocker is able to restrain or delay the progression to hypertension. Secondary objectives are to investigate whether any long-term effect on blood pressure is related to the effect of treatment on renal haemodynamic function, or on the left ventricle mass.

Conditions

Interventions

DRUG

Candesartan

placebo controlled double blind

Sponsors & Collaborators

  • University of Aarhus

    collaborator OTHER

  • AstraZeneca

    collaborator INDUSTRY

  • Karin Skov

    lead OTHER

Principal Investigators

  • michael mulvany, prof · Dept. of Pharmacology, Aarhus University

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
36 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2000-11-30
Primary Completion
2004-01-31
Completion
2014-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00150631 on ClinicalTrials.gov